Authors
Latest:
Dr. Stein on Blinatumomab for Relapsed/Refractory ALLAnthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Latest:
Dr. Shields on the Standard of Care in Newly Diagnosed mCRCAnthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Latest:
Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid TumorsAnthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.
Latest:
Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLCAntoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.
Latest:
Melanoma: Improving Clinical Outcomes Through Advances in Immunotherapeutics and Targeted TherapyMetastatic melanoma has limited treatment options, but advances in the understanding of the oncogenic mutations that drive this cancer and how the immune system can be better modulated to fight melanoma provide a new generation of active approaches for patients.
Latest:
Dr. Ribas on Immune-Related Adverse Events in MelanomaAntoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.
Latest:
Dr. Wolff Discusses the Importance of HER2 TestingDr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing
Latest:
Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian CancerAntonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.
Latest:
Dr. Iavarone on the Role of the ID2 Protein in Brain CancerAntonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Latest:
Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast CancerAntonio Llombart-Cussac, MD, PhD, chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study, which assessed first-line eribulin (Halaven) for taxane-resistant patients with HER2-negative metastatic breast cancer.
Latest:
Dr. Palumbo on Significance of Daratumumab Triplet in Multiple MyelomaAntonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.
Latest:
Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLCAntonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.
Latest:
Potential Molecular Markers in Liver CancerAnuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.
Latest:
Dr. Ganti on Lung Cancer Abstracts From the 2018 ASCO Annual MeetingApar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr. Tsimberidou on the Impact Trial in Patients With Advanced CancerApostolia Maria Tsimberidou, MD, PhD, tenured professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the IMPACT trial in patients with advanced cancer.
Latest:
Dr. Tsimberidou on the Next Steps for Personalized CareDr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLLArantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).
Latest:
Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALLAref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Dr. Melnick on Targeting EZH2 in DLBCLAri Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.
Latest:
Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.
Latest:
Dr. Zimran Discusses Gaucher Disease BiomarkersDr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr. Perry on Implications of WHO Tumor Classifications in Brain CancerArie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.
